The role of vascular endothelial growth factor in restenosis: the controversy continues.
Shiojima
Ichiro
I
Walsh
Kenneth
K
D000256:Adenoviridae / Q000235:genetics; D043925:Angiogenesis Inducing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D002404:Catheterization / Q000009:adverse effects; D023903:Coronary Restenosis / Q000139:chemically induced* / Q000209:etiology; D003331:Coronary Vessels / Q000293:injuries; D015316:Genetic Therapy / Q000009:adverse effects; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia; D051379:Mice; D018345:Mice, Knockout; D051381:Rats; D040262:Receptors, Vascular Endothelial Growth Factor / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000502:physiology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000502:physiology / Q000627:therapeutic use
D043925:Angiogenesis Inducing Agents; D011993:Recombinant Fusion Proteins; C475927:VEGF-Trap fusion protein, recombinant; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor